1. Home
  2. BXP vs RGEN Comparison

BXP vs RGEN Comparison

Compare BXP & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boston Properties Inc.

BXP

Boston Properties Inc.

HOLD

Current Price

$58.06

Market Cap

8.2B

Sector

Real Estate

ML Signal

HOLD

Logo Repligen Corporation

RGEN

Repligen Corporation

HOLD

Current Price

$116.32

Market Cap

6.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BXP
RGEN
Founded
1970
1981
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medical/Dental Instruments
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.2B
6.6B
IPO Year
1998
1995

Fundamental Metrics

Financial Performance
Metric
BXP
RGEN
Price
$58.06
$116.32
Analyst Decision
Buy
Buy
Analyst Count
18
12
Target Price
$71.83
$167.67
AVG Volume (30 Days)
1.8M
839.1K
Earning Date
04-28-2026
05-05-2026
Dividend Yield
4.83%
N/A
EPS Growth
1833.33
286.96
EPS
1.74
0.86
Revenue
$3,482,279,000.00
$141,236,000.00
Revenue This Year
$11.00
$14.30
Revenue Next Year
$2.91
$14.52
P/E Ratio
$33.41
$137.66
Revenue Growth
2.19
35.10
52 Week Low
$49.93
$109.50
52 Week High
$79.33
$175.77

Technical Indicators

Market Signals
Indicator
BXP
RGEN
Relative Strength Index (RSI) 62.19 42.70
Support Level $57.59 $111.29
Resistance Level $59.88 $130.12
Average True Range (ATR) 1.54 6.05
MACD 0.46 -0.80
Stochastic Oscillator 78.84 21.62

Price Performance

Historical Comparison
BXP
RGEN

About BXP Boston Properties Inc.

BXP owns 179 properties consisting of approximately 52.6 million rentable square feet of space. The portfolio is dominated by office buildings and is spread across major cities such as New York, Boston, San Francisco, Los Angeles, Seattle, and the Washington, D.C., region. The real estate investment trust also owns limited retail, hotel, and residential properties.

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.

Share on Social Networks: